Medical Patent News

RSS

USPTO issues patent to NJIT's unique device for treatment of brain injury

NJIT Professor Gordon Thomas and NJIT Research Professor Reginald Farrow, both in the department of physics, and NJIT alumnus Sheng Liu, formerly a doctoral student of both researchers and now an engineer at a biotech company, were awarded a patent today for the NJIT SmartShunt-, a unique device to help patients with brain injuries.

4 Jan 2012

Regeneron, Genentech enter non-exclusive license and partial settlement agreement for EYLEA

Regeneron Pharmaceuticals, Inc. today announced that the Company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEA (aflibercept) Injection.

3 Jan 2012

ARCA biopharma extends pharmacogenetic intellectual property protection around bucindolol

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for treating patients with bucindolol based on genetic targeting and focused on a specific genotype - homozygous wildtype for Deletion 322-325 in the alpha-2C adrenergic receptor.

31 Dec 2011

USPTO issues patent to Novus Scientific's TIGR Matrix Surgical Mesh

The Intellectual Property portfolio of TIGR Matrix Surgical Mesh has been further complimented with the granting of a second U.S. patent related to material degradation and mechanical behaviour.

27 Dec 2011

Acacia increases infusion pump technology patent portfolio

Acacia Research Corporation announced that a subsidiary has acquired patents relating to infusion pump technology from a major medical device company.

19 Dec 2011

Supreme Court hears arguments related to patent dispute

The Minneapolis Star Tribune reports that the question is whether patents can be applied to concepts drawn from nature and notes that the case could redefine ownership of technological or scientific innovations.

9 Dec 2011

USPTO issues Diabetes Patent to Omni Bio

Omni Bio Pharmaceutical, Inc. today announced that U.S. Patent No. 8,071,551, entitled "METHODS AND COMPOSITIONS FOR TREATING DIABETES," was issued by the United States Patent and Trademark Office on December 6, 2011. The Diabetes Patent expires in May 2022.

9 Dec 2011

Ampio awarded composition of matter patent for Ampion in Europe

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced receipt of notification of the granting of a European patent with broad claims directed to compositions containing DA-DKP, a cyclic dipeptide diketopiperazine which is the active ingredient of Ampion™.

7 Dec 2011

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.

7 Dec 2011

NASA-developed technology for treatment of hardened arteries in the heart

NASA has signed a patent license agreement that will allow a California company use of NASA-developed technology that could be used to treat hardened arteries in the heart.

3 Dec 2011

Mylan confirms generic Generess Fe patent challenge

Mylan Inc. today confirmed that it and Famy Care Ltd. have been sued by Warner Chilcott Company LLP, in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Norethindrone and Ethinyl Estradiol Chewable Tablets, 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets. This product is the generic version of Generess Fe, a 28-day regimen indicated for use by women to prevent pregnancy.

2 Dec 2011

USPTO issues Notice of Allowance to Emboline's aortic devices for TAVR procedures

Emboline, Inc., an emerging medical device company, has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its aortic embolic protection devices for percutaneous heart valve repair and replacement.

1 Dec 2011

Santaris Pharma wins two LNA patent re-examination cases in the U.S.

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has won two significant patent re-examination cases brought by Isis Pharmaceuticals.

1 Dec 2011

Medizone receives Canadian patent for AsepticSure hospital disinfection product

Medizone International, Inc. reports that the Canadian Patent Office has granted Canadian Patent No 2735739 for processes and systems relating to the platform technology of its revolutionary AsepticSure hospital disinfection product.

30 Nov 2011

Avita Medical announces acquisition of intellectual property from McComb Foundation

Avita Medical Ltd., the regenerative medicine company, is pleased to announce that it has successfully completed the transfer and acquisition of intellectual property currently licensed through the McComb Foundation of Western Australia.

29 Nov 2011

University of Rochester receives U.S. patent for HPV vaccine research

The University of Rochester has been awarded a U.S. patent for research essential to both human papillomavirus vaccines on the market.

23 Nov 2011

AMP opposes NIH proposal to license cancer-related proteonomics patent

The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.

23 Nov 2011

USPTO issues patent to BioFactura's StableFast platform

BioFactura, Inc. was awarded a US patent covering the core technologies of its proprietary StableFast Biomanufacturing Platform. The US Patent and Trademark Office allowed 32 claims broadly covering composition of matter, methods, commercial kits, and media formulations.

23 Nov 2011

Pall applies patent with USPTO for disposable, closed cell collection and seeding system

Pall Corporation, a global leader in filtration, separation and purification, has applied for a patent with the United States Patent and Trademark Office (USPTO) for a disposable, closed cell collection and seeding system that is being developed for use in ground-breaking vein regeneration procedures.

From Pall Corporation 23 Nov 2011